Fierce Biotech

Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
GlobalData on MSN

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Stocktwits on MSN

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...
Investor's Business Daily on MSN

Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.
PharmExec

Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...